Therapy of chronic hepatitis B: new goals and new treatments.
Treatment of chronic hepatitis B has shown a rapid development in the last years leading to a shift of treatment strategies from interferon to hepatitis B virus (HBV)-polymerase inhibitors. In particular, treatment with HBV-polymerase inhibitors has changed the indication on how to treat a patient and when to stop therapy. Long-term treatment with HBV-polymerase inhibitors may often be required, even if it raises the possibility of resistance and subsequent treatment failure. This review provides a strategy on how to manage HBV therapy with the currently available treatment options.
Mauss
S
S
Center for HIV and Hepatogastroenterology, Grafenberger Allee 128a, 40237 Duesseldorf, Germany. stefan.mauss@center-duesseldorf.de
D000998:Antiviral Agents / Q000627:therapeutic use*; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D015684:Gene Products, pol / Q000037:antagonists & inhibitors; D015658:HIV Infections / Q000188:drug therapy; D006513:Hepatitis B e Antigens / Q000276:immunology; D006515:Hepatitis B virus / Q000187:drug effects / Q000502:physiology; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D019259:Lamivudine / Q000627:therapeutic use; D014779:Virus Replication
D000998:Antiviral Agents; D015684:Gene Products, pol; D006513:Hepatitis B e Antigens; C066027:P protein, Hepatitis B virus; D019259:Lamivudine; D007372:Interferons